Hallermayr, A.; Keßler, T.; Fujera, M.; Liesfeld, B.; Bernstein, S.; von Ameln, S.; Schanze, D.; Steinke-Lange, V.; Pickl, J.M.A.; Neuhann, T.M.;
et al. Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays. Cancers 2023, 15, 5024.
https://doi.org/10.3390/cancers15205024
AMA Style
Hallermayr A, Keßler T, Fujera M, Liesfeld B, Bernstein S, von Ameln S, Schanze D, Steinke-Lange V, Pickl JMA, Neuhann TM,
et al. Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays. Cancers. 2023; 15(20):5024.
https://doi.org/10.3390/cancers15205024
Chicago/Turabian Style
Hallermayr, Ariane, Thomas Keßler, Moritz Fujera, Ben Liesfeld, Samuel Bernstein, Simon von Ameln, Denny Schanze, Verena Steinke-Lange, Julia M. A. Pickl, Teresa M. Neuhann,
and et al. 2023. "Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays" Cancers 15, no. 20: 5024.
https://doi.org/10.3390/cancers15205024
APA Style
Hallermayr, A., Keßler, T., Fujera, M., Liesfeld, B., Bernstein, S., von Ameln, S., Schanze, D., Steinke-Lange, V., Pickl, J. M. A., Neuhann, T. M., & Holinski-Feder, E.
(2023). Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays. Cancers, 15(20), 5024.
https://doi.org/10.3390/cancers15205024
